胶质母细胞瘤
癌症研究
免疫组织化学
光学相干层析成像
荧光寿命成像显微镜
生物发光成像
病理
医学
生物发光
脑瘤
白质
荧光素酶
荧光
磁共振成像
放射科
生物
细胞培养
物理
量子力学
遗传学
转染
生态学
作者
Diana V. Yuzhakova,Elena B. Kiseleva,Marina V. Shirmanova,Vladislav I. Shcheslavskiy,Daria A. Sachkova,Ludmila B. Snopova,Evgeniya Bederina,Maria M. Lukina,Varvara V. Dudenkova,G. M. Yusubalieva,Tatyana N. Belovezhets,Daria Matvienko,Владимир П. Баклаушев
标识
DOI:10.3389/fonc.2022.897839
摘要
Development of the novel diagnostic and therapeutic approaches in neuro-oncology requires tumor models that closely reproduce the biological features of patients’ tumors. Patient-derived xenografts (PDXs) are recognized as a valuable and the most “close-to-patient” tool for preclinical studies. However, their establishment is complicated by the factors related to both the surgical material and technique of the orthotopic implantation. The aim of this work was to develop a patient-derived glioblastoma multiform (GBM) model that stably co-expresses luciferase and a far-red fluorescent protein for monitoring of tumor progression in the brain and, using this model, to validate new diagnostic methods—macroscopic fluorescence lifetime imaging (macro-FLIM) and cross-polarization optical coherence tomography (CP OCT). The established model was similar to the original patient’s GBM in terms of histological and immunohistochemical features and possessed reproducible growth in nude mice, which could be observed by both fluorescence and bioluminescence imaging. Our results demonstrated the high potential of macro-FLIM and CP OCT for intraoperative differentiation of GBM from the white matter. Thus, the dual-labeled PDX model of GBM proved to be an excellent approach for observation of tumor development by optical methods.
科研通智能强力驱动
Strongly Powered by AbleSci AI